Oasmia Pharmaceutical AB (OASMY PINK) stock market data APIs
$0.0001
0(0%)
as of February 6, 2026
Try our APIs with
free plan!
Oasmia Pharmaceutical AB Financial Data Overview
Price chart is built with
Anychart
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was founded in 1988 and is headquartered in Solna, Sweden.
Prev. Close
0.0001
Open
0.0001
High
0.0001
Low
0.0001
52 wk Range
0.0001-0.0415
Market Cap
151 K
Shares Outstanding
206 M
Revenue
-131 000
EPS
0
Dividends (Yield)
0
Beta
1.04
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Oasmia Pharmaceutical AB data using free add-ons & libraries
Get Oasmia Pharmaceutical AB Fundamental Data
Oasmia Pharmaceutical AB Fundamental data includes:
- Net Revenue: -131 000
- EBITDA: -33 894 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-12
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oasmia Pharmaceutical AB News
New
Kazia Therapeutics Licenses Cantrixil To Oasmia Pharmaceutical For Ovarian Cancer
Kazia Therapeutics Ltd (NASDAQ: KZIA) has entered an exclusive worldwide licensing agreement with Oasmia Pharmaceutical AB (OTCMKTS: OASMY) for Cantrixil under development the treatment of ovarian can...
Kazia Therapeutics Licenses Cantrixil To Oasmia Pharmaceutical For Ovarian Cancer
Kazia Therapeutics Ltd (NASDAQ: KZIA) has entered an exclusive worldwide licensing agreement with Oasmia Pharmaceutical AB (OTCMKTS: OASMY) for Cantrixil under development the treatment of ovarian can...
Oasmia Pharmaceutical AB to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 19, 2021 / Oasmia Pharmaceutical AB (STO:OASM) will be discussing their earnings results in their 2021 Third Quarter Earnings call to be held on February 19, 2021 ...
Oasmia Pharmaceutical AB to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 19, 2021 / Oasmia Pharmaceutical AB (STO:OASM) will be discussing their earnings results in their 2021 Third Quarter Earnings call to be held on February 19, 2021 ...
Get Oasmia Pharmaceutical AB fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
